nidanilimab

{
  "id": "MLC-T-ONC-015506",
  "term": "nidanilimab",
  "field": "Oncology and biomedicine",
  "definition": "A low fucose, fully-humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) against the interleukin 1 receptor accessory protein (interleukin-1 receptor associated protein; IL1RAP), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, nidanilimab targets and binds to IL1RAP, thereby preventing IL1RAP-mediated signaling, and disrupting IL-1 and IL-33 mediated nuclear factor kappa beta (NFkB) activation. This prevents the secretion of tumor stimulating cytokines, decreases tumor inflammation and inhibits tumor cell proliferation. In addition, nidanilimab induces antibody-dependent cellular cytotoxicity (ADCC), and stimulates natural killer (NK) cells to attack tumor cells, thereby killing the IL1RAP-poisitive tumor cells. IL1RAP, a co-receptor of the IL-1 receptor (IL1R1) and the IL-33 receptor (ST2), is upregulated in certain tumor cells, and plays a key role in tumor cell proliferation.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/nidanilimab/"
}